Abbott Wins Approval for UltiSynq Defibrillation Lead

The lead is designed to deliver both conduction system pacing and defibrillation therapy, having received FDA approval and a CE Mark.

Updated on Nov. 12, 2026 in Heart Disease

Abbott Wins Approval for UltiSynq Defibrillation Lead

Abbott has received U.S. FDA approval and a CE Mark for its UltiSynq defibrillation lead, a device designed to deliver both conduction system pacing and defibrillation therapy. The FDA had previously designated the lead a breakthrough device.

Why it matters

Roughly 150,000 implantable cardioverter-defibrillators (ICDs) are implanted each year in the United States and about 140,000 in Europe, so the approvals cover large patient populations. The lead is intended to combine pacing and defibrillation functions in one device.

In the ASCEND CSP IDE trial, lead implantation succeeded in 98.5% of 205 attempts, with 86% of successfully implanted patients achieving LBBP or likely LBBP. The three-month major complication-free rate was 97.5%, and defibrillation succeeded in all 120 patients tested, though longer-term outcomes were not reported.

The players

Abbott

Abbott is a global healthcare company that develops and manufactures medical devices, including cardiac rhythm management products.

The details

UltiSynq uses true bipolar sensing with two closely spaced electrodes within the lead to detect ventricular signals and includes a short shock coil to support positioning precision. The ASCEND CSP IDE trial enrolled patients at centers in the United States, Canada, Europe, and the Asia-Pacific region.

Timeline

  1. April 2026: Three-month ASCEND CSP IDE results were presented at the Heart Rhythm Society meeting.

  2. November 12, 2026: Abbott announced FDA approval and CE Mark for UltiSynq.

Clinical Context

The UltiSynq lead extends conduction system pacing, including left bundle branch area pacing (LBBP), into a combined pacing and defibrillation device rather than a conventional right ventricular lead. Its trial results show that combining these functions in one lead is feasible in a large implant cohort.

For patients who need an implantable defibrillator, a lead that combines pacing and defibrillation could mean one device instead of two. Patients should discuss with their cardiologist whether such a device is appropriate for them, since availability will depend on regional regulatory approval and clinical guidance.

The takeaway

Combining conduction system pacing with defibrillation in a single lead addresses two needs at once, but results so far cover only three months of follow-up. Patients and clinicians should watch for longer-term outcome data before assuming broader adoption.

Further reading

For background on the conditions these devices treat, see Heart Disease.